Generating New Data to Help Support Vaccination Adherence

Top-line study results support potential for co-administration of PREVNAR 20™ and seasonal flu vaccine in single appointment in line with CDC guidance

Top-line results from a phase 3 clinical trial we conducted demonstrated that PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) and a seasonal influenza (flu) vaccine has the potential to be administered at the same time without affecting the immune protection provided by either vaccine or changing the safety profile.

On June 8, 2021, the U.S. Food and Drug Administration (FDA) approved PREVNAR 20, our pneumococcal 20-valent conjugate vaccine, for the prevention of invasive disease and pneumonia in adults aged 18 years or older. 9 PREVNAR 20 represents the first approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia,1,2,3,4,5,6,7 including seven responsible for 40 percent of pneumococcal disease cases and deaths in the U.S.8

HCP with dark curly hair and glasses talking with her elderly patient

We are committed to helping protect more adults across many respiratory diseases.

“Both PREVNAR 20 and the influenza vaccine are important for helping protect adults against pneumococcal pneumonia and the flu, respectively; however, vaccination rates decline when someone needs to make multiple appointments to receive these vaccines,” said Luis Jodar, Ph.D., Senior Vice President and Chief Medical Officer, Pfizer Vaccines. “The results of this trial provide support for current Centers for Disease Control and Prevention (CDC) clinical guidance allowing co-administration during a single doctor or pharmacy appointment, so that more adults are able to help protect themselves against both of these respiratory diseases.”

This study is one example of our commitment to help improve vaccine adherence among recommended populations, as well as further vaccine development to help address needs across certain respiratory diseases.

  1. U.S. Centers for Disease Control and Prevention. Active Bacterial Core (ABCs) surveillance. National Center for Immunization and Respiratory Diseases. Atlanta, GA.

  2. Ladhani, SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441-451.

  3. Menéndez R, España PP, Pérez-Trallero E, et al. The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study. Vaccine. 2017;35(39):5264-5270.

  4. Azzari C, Cortimiglia M, Nieddu F, et al. Pneumococcal serotype distribution in adults with invasive disease and in carrier children in Italy: Should we expect herd protection of adults through infants’ vaccination? Hum Vaccin Immunother. 2016;12(2):344-350.

  5. Pivlishi T. Impact of PCV13 on invasive pneumococcal disease (IPD) burden and the serotype distribution in the U.S. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. October 24, 2018.

  6. European Centre for Disease Prevention and Control. Invasive pneumococcal disease. In: ECDC. Annual epidemiological report for 2016. Stockholm: ECDC; 2018.

  7. Beall B, Chochua S, Gertz RE Jr, et al. A population-based descriptive atlas of invasive pneumococcal strains recovered within the U.S. during 2015-2016. Front Microbiol. 2018;19(9).

  8. Pfizer Inc. NCT03828617 Study Design. Available at is external) under the identifier NCT03828617.

  9. U.S. Food and Drug Administration. PREVNAR 20 Prescribing Information. Accessed March 7, 2022.